NCT03311152View on ClinicalTrials.gov

Circulating Cell-free DNA-based Epigenetic Biomarker MSEPT9 for Hepatocellular Carcinoma Detection in Cirrhosis

NACompletedINTERVENTIONAL
Enrollment

529

Participants

Timeline

Start Date

February 12, 2018

Primary Completion Date

October 17, 2024

Study Completion Date

October 17, 2024

Conditions
Hepatocellular CarcinomaCirrhosis
Interventions
DIAGNOSTIC_TEST

"Epi proColon 2.0 CE test from Epigenomics, Inc (Berlin, Germany)"

The mSEPT9 assay consists of DNA extraction from plasma, bisulfite conversion of DNA, purification of bis-DNA, and real-time PCR.

Trial Locations (1)

54511

University Hospital of Nancy (CHRU de Nancy), Vandœuvre-lès-Nancy

Sponsors
All Listed Sponsors
collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

collaborator

Groupement Interrégional de Recherche Clinique et d'Innovation

OTHER

collaborator

Epigenomics, Inc

INDUSTRY

collaborator

New Day Diagnostics

NETWORK

lead

Central Hospital, Nancy, France

OTHER